Cancer Res Treat.  2006 Dec;38(4):198-200.

Lapatinib : Overview and Current Role in Metastatic Breast Cancer

• Chan A

Abstract

No Author listed.

MeSH Terms

Breast Neoplasms*
Breast*

Reference

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235:177–182. PMID: 3798106.

2. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol. 2002; 20(18):Suppl. 1S–13S. PMID: 12235219.

3. Nahta R, Esteva FJ. HER-2 targeted therapy: lessons learned and future directions. Clin Cancer Res. 2003; 9:5078–5084. PMID: 14613984.

4. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006; 66:1630–1639. PMID: 16452222.

5. Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005; 23:5305–5313. PMID: 15955900.

6. Spector NL, Xia W, Burris H 3rd, Hurwitz H, Dees EC, Dowlati A, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol. 2005; 23:2502–2512. PMID: 15684311.

7. Lin LA, Carey MC, Liu J, Younger SE, Come E, Bullitt AD, et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. 2006. In : Proc ASCO; –503.

8. Geyer CD, Cameron D, Lindquist S, Chan T, Pienkowski CG, Romieu A, et al. Forster A Phase III Randomized, Open-Label, International Study Comparing Lapatinib and Capecitabine vs. Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer (EGF100151). 2006. In : Proceeding ASCO;